Skip to content

Effect of Roxadustat treatment on patients with diabetes mellitus combined with chronic kidney disease

Effect of Roxadustat treatment on patients with diabetes mellitus combined with chronic kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097135
Enrollment
Unknown
Registered
2025-02-13
Start date
2025-02-14
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non dialysis type 2 diabetes patients with chronic kidney disease

Interventions

shift group:NA
rHuEPO group:NA

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. age >=18 years; 2. Definitely diagnosed as type 2 diabetes with proteinuria and/or abnormal renal function: random urinary albumin/creatinine ratio >= 30 mg/g or urinary albumin excretion rate >= 30 mg/24h, and 2 out of 3 repeated examinations within 3-6 months before enrollment >= critical value, or glomerular filtration rate<60 mL/min/1.73 m ^ 2 for more than 3 months. 3. Diagnosis of renal anemia and treatment with rHuEPO or Roxadustat.

Exclusion criteria

Exclusion criteria: 1. have anemia due to other diseases, such as thalassemia, sickle cell anemia, tumor-related anemia, and myelodysplastic syndromes; 2. recent (<= 3 months) gastrointestinal hemorrhage and/or recent severe acute blood loss from other causes; 3. are expected to begin renal replacement therapy within 24 weeks.

Design outcomes

Primary

MeasureTime frame
glycosylated hemoglobin;Neutrophil Count/Lymphocyte Count;Platelet count x neutrophil count/lymphocyte count;

Countries

China

Contacts

Public ContactRong Shu

Shanghai General Hospital

jingweisy@126.com+86 21 63240090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026